Stock ALVO ALVOTECH
Add to a list
To use this feature you must be a member
Log inSign up

All News Alvotech Nyse

Equities

ALVO

LU2458332611

Market Closed - Nyse
Other stock markets
 04:00:00 2024-05-01 pm EDT 		5-day change 1st Jan Change
14.48 USD -0.14% Intraday chart for Alvotech +8.21% +54.37%
Apr. 30 Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals MT
Apr. 30 Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alvotech - U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-FreeInterchangeable Biosimilar to Humira
AQ
Alvotech And Teva's Selarsdi™ (ustekinumab-aekn), Biosimilar To Stelara® Approved By FDA
AQ
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals
MT
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent
MT
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
GL
FDA Approval Of Alvotech/Teva Ustekinumab Biosimilar
AQ
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
RE
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi
AQ
Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study
MT
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
GL
Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi
CI
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira
AQ
Sector Update: Health Care Stocks Advance Late Afternoon
MT
Sector Update: Health Care Stocks Rise Friday Afternoon
MT
Sector Update: Health Care
MT
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US
MT
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US
MT
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
GL
Alvotech Signs U.S. Agreement to Expand Access for Newly Approved High-Concentration Interchangeable Biosimilar to Humira®
CI
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALVO Stock
  4. ALVO Stock
  5. News Alvotech